The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Posted this after midnight last night and it got removed with the rest of that thread. The fact is that the person or people that the uber wombles think are positive are influential on the bb are targeted by by their paid c wombles. Thoth was in that space as he was influential, well researched and generous at sharing this with the bb. The uber wombles reckon that attacking the sources of research and information would weaken the sentiment and the share price to help with a short or whatever. Thoth is really missed. SOG is in that space and it is the highest compliment that I can pay him. We are also fortunate to have other informative and positive posters on here and it is important to stand up to the bullies and sneering wombles. Finally I believe that all sides of the argument should be heard and we can return to rational and genuine discussion.
I would imagine HDB that record keeping of the various aspects of compliance that can be checked or inspected by the MHRA would be a given. Having it on IT would be a requirement for a world class CRO I would imagine.
My worry is if So try to hold SRA 737 it might be a ploy by GSK/So the ignore it indefinitely so that they can test their own supposedly alternative. You would need top Lawers involved. Fool me once shame on you, fool me twice shame on me.
Some really positive posts today by a good number of contributers which is welcome and gives a balance to the debate at a challenging time for many of us. You are dealing with posters here who have all kinds of different motives including top slicers, shorters, hopeful newbies who are hoping to get in at rock bottom. You also have trolls or paid derampers who will always be negetive regardless. There must be a very good chance that the CTA will be accepted. It would surely be devastating for the CRO who are supposidlhy world class according to Tim to be negligent. Seems unlikely and I would imagine that more than their reputation would be on the line. SRA 737 is obviously an absolute gem, as some great posts here today indicatesan andrelicensing it must be a given.
Keep the faith.
Many of us are severely dissaponted at what has transpired those last few days. Agree that it is incumbent on the BOD to keep us informed. The CTA was lodged by the 28th of July and Tim said that he expects a decision shortly. Think many on here would welcome a sale of the company, but the offer must reflect its real value going forward. It is important that all voices are heard, and that includes yours Warthog. Expect the CTA news will
bring stability and forward momentum. Remember we have a very valuable pipeline. We have been down at this level on a few occasions. Momentum and confidence can be regained.
Sadoldgit, your contribution to this platform is immense. Your posts are always thought provoking, based on scientific and psychological analysis.
HBD, interesting point about the use of language. I notice in Tim's response that there is no ambiguity, it's very definite. Makes me wonder whether GSK were obliged to return SRA737, having exceeded the time limit on developing it. Agree with SOG that another pharma will licence it, which should be beneficial to us.
Excellent positive posts this morning. The real message coming through is that SRA 737 is alive and competitive with anything out there. Great work has been done and will not be undone with GSK choosing it's own expensively acquired alternative. We know that triple therapy has effectively prevented CHK1 inhibition. Much to be confident about. The handing back headline spooked some, was used as a shorters tool and was probably used by the institutions to get cheap shares. Wonder how many stop losses were raided. SRA 737 as effective today as it was one week ago and in combo highly effective in degrading tumors aggresivly. The handing back can be seen, I would imagine, as an opportunity get a better deal.
That Ben and HBD is a good question in relation to the ownership of the combo. Situation was looking grim early this morning but fall has been contained. One thing for sure, SAR737 pretty peerless in double/triple combo. Whatever GSK have in the locker will not best it as SOG has observed. Hard to imagine that there won't be suitors there who will love to licence it for combo/triple testing. Don't forget that it ain't half bad in mono as seen in ano genital which has no better treatment. The market has digested the latest information. No way has SRA737 failed.
Absolutely, a legend on this board. Would be great if it can happen after we reach the promised land to have a bottle or two or three somewhere with Thoth there.
Incidentally your posting and research is 1st class SOG. And citizen also doing great research.
Hard not to see this going higher, much higher soon. Three potential blockbusters with huge potentil that hó ld the prom
Ise providing a cure to so many of the most serious cooditions that are out there both autoimmune and cancer, with the promise of low tox and with applications in combo and as sole medicines. Phenomenally exciting and promising.
Could it be a con job? hopefully not. 50 grand, which is feck all for them getting their hands on it to investigate solubility. Wonder if Tim and co. are familiar with any recent developments in the Orient that could relate to Sareum.